EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group



Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group



Thrombosis and Haemostasis 73(5): 779-784



Monoclonal antibody purified factor IX concentrate, Mononine (Armour Pharmaceutical Company, Kankakee, Illinois, USA), is a recently developed replacement factor concentrate for the treatment of patients with hemophilia B. The pharmacokinetic properties of monoclonal antibody purified factor IX concentrate (MAb Factor IX concentrate) have been evaluated in only small samples of patients, and little is known about those factors that might influenced in vivo recovery of factor IX after infusion is a larger patient population. In vivo recovery of factor IX was therefore evaluated for 80 different indications in 72 patients who received MAb Factor IX concentrate for the management of spontaneous or trauma-induced bleeding, or as prophylaxis with surgery. The average recovery after infusions for presurgical pharmacokinetic analysis (mean +/- standard deviation) was 1.28 +/- 0.56 U/dl rise per U/kg infused (range 0.41-2.80), and the average recovery after all infusions for treatment was 1.23 +/- 0.49 U/dl rise per U/kg infused (range - 0.35-2.92). Recovery values for multiple MAb Factor IX doses in a given patient were also variable; the average recovery was 1.22 +/- 0.53 U/dl rise per U/kg given, and standard deviations ranged from 0.03 to 1.26. Patient age, weight, and MAb Factor IX concentrate dose minimally but significantly influenced factor IX recovery. There was no significant effect of either race, history of previous thrombotic complications during treatment with other replacement factor concentrates, or bleeding state on recovery. All of the patients treated with this preparation experienced excellent hemostasis, and no thrombotic complications were observed.

(PDF emailed within 1 workday: $29.90)

Accession: 044942180

Download citation: RISBibTeXText

PMID: 7482403



Related references

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thrombosis & Haemostasis 73(5): 779-784, 1995

Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. American Journal of Hematology 49(1): 92-94, 1995

Half-life, recovery and efficacy of continuous infusion monoclonal antibody purified factor IX in hemophilia B surgical, trauma, or severe spontaneous hemorrhage patients. Blood 90(10 SUPPL 1 PART 1): 35A, Nov 15, 1997

In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates. Thrombosis and Haemostasis 66(6): 730-733, 1991

Compassionate treatment with a monoclonal antibody-purified factor IX concentrate in hemophilia B surgical patients who have experienced thrombotic complications with prothrombin complex concentrates. Blood 82(10 SUPPL 1): 154A, 1993

Lack of immune response to mouse IgG in previously untreated hemophilia A and hemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations. Blood 86(10 SUPPL 1): 868A, 1995

Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Seminars in Hematology 27(2 Suppl 2): 30-35, 1990

Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage. Blood 98(11 Part 1): 532a, November 16, 2001

Preclinical studies of a monoclonal antibody-purified factor IX, Mononine. Seminars in Hematology 28(3 Suppl 6): 6-14, 1991

Infusion of monoclonal antibody immunoaffinity purified factor ix in rabbits comparison with commercial concentrates. Thrombosis & Haemostasis 58(1): 349, 1987

Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Pediatric Hematology/Oncology 15(1): 107-110, 1993

Low recovery in vivo of highly purified factor VIII in patients with hemophilia. Journal Of Pediatrics. 121(5 Part 1): 814-818, 1992

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thrombosis and Haemostasis 75(1): 30-35, 1996

Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII. American Journal of Hematology 45(2): 142-145, 1994